TP 2846
Alternative Names: TP-2846Latest Information Update: 23 Sep 2022
At a glance
- Originator Tetraphase Pharmaceuticals
- Class Antineoplastics; Tetracyclines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 23 Sep 2022 Discontinued - Preclinical for Acute myeloid leukaemia in USA (IV) (La Jolla Pharmaceutical Company website, September 2022)
- 28 Jul 2020 Tetraphase Pharmaceuticals has been acquired by La Jolla Pharmaceutical Company
- 31 Dec 2019 TetraPhase Pharmaceuticals intends to submit an IND application for TP 2846, following partner identification